Formulation And Evaluation of Matrix Type Rosuvastatin Sustained Released Tablets

1. 1. Sustained Release Matrix Tablet

This is carried out to maximize the drug's usefulness. The unique drug delivery method either guides the medication to particular locations or allows for prolonged, regulated drug distribution, both of which may improve the therapeutic efficacy of the newly introduced pharmaceuticals. This is due to the system's affordable price. The majority of solid oral sustained release systems limit drug release by diffusion, dissolution, or a combination of the two. When a medication is administered in this manner, the body immediately absorbs the proper quantity of the medication, enabling it to have the intended pharmacological effect. The remaining fraction is gradually released because its release is necessary to sustain the peak initial pharmacological activity for a longer amount of time than would be anticipated from a single dose of the drug. There are many different names for the many kinds of medication delivery systems designed to have a longer duration of action. The majority of time-release medications developed today include their active ingredients in a matrix consisting of one or more insoluble substances. This configuration ensures that for the medication to be released, it must travel through the matrix's pores. Some polymer-based tablets that contain pharmaceuticals include a porous membrane on one side and a laser-drilled hole on the other. When the GIT acids penetrate the permeable membrane, the medication is released via the hole the laser produced. The polymer container is maintained intact while the whole pharmaceutical dosage is gradually delivered into the body. As a consequence, the medication may be eliminated from the body naturally via digestion. In order to achieve fast and full systemic medicine absorption, the majority of traditional oral pharmaceutical products, such as tablets and capsules, are created with a formulation that permits the active component to be released relatively rapidly after oral administration. Due to these medications' instant release properties, drug absorption and the beginning of their pharmacodynamic effects occur rather quickly.

1. 2. Diffusion Systems

There are typically two types of compound dispersal devices: reservoir equipment and matrix devices.

1. 1. 1. Reservoir Type

Here, the pharmaceutical core containing the active component is shielded by a polymeric barrier. The most typical techniques for building reservoir-type devices are listed below. small amounts of medication in capsules.

1. 1. 2. Press-coating

The pharmaceutical business often utilizes the microencapsulation technology to enclose individual medication particles. Even though dissolution is the mechanism in charge of regulating the rate of release, diffusion is often implicated in the process of drug release. This is true even though the rate at which the drug is delivered is ultimately determined by the process of breakdown. Methyl chloride, poly hydroxyl methacrylate, polyvinyl acetate, and hydroxyl permeable methyl acrylate (HPMC) are utilized together with a variety of waxes. polymer made of methacrylic acid. Polymerized vinyl acetate.

1. 1. 3. Matrix Type

The dissolved or dispersed medication is then evenly distributed across an inert polymeric matrix. According to this notion, the liquid medication first separates from the solid drug's top layer during dives. Compressible polymers have the possibility of direct compression. Utilizing the melt granulation technique, wax is treated.

1. 3. Osmotic Systems

If a steady osmotic pressure is maintained and a few more characteristics of the doctor are present, it is feasible to use osmotic pressure as the driving mechanism to supply a continuous flow of medication. osmotically active medicines or the center of an osmotically inert drug surrounding by an osmotically active sail are enclosed in a semi-permeable membrane with very tiny pores. Drugs won't spread as rapidly because of the barrier, but neither will water. An osmotic imbalance causes water to enter the pill when it comes in contact with water or other biological fluids. Regardless of the fluid, this occurs.⁹

1. 4. Ion-Exchange Resins

The salt-forming groups of ion exchange resins are repeated throughout the polymer chain, making it a cross-linked, water-insoluble polymer. The drug may get bound if it is repeatedly exposed to the drug in a chromatographic column or if the resin is kept in contact with the drug solution for a prolonged length of time. The drug-resin is washed to remove potentially contaminated ions before being dried to generate particles or beads. The rate at which a medication leaves the system The resin's properties and the ionic environment in the gut, which includes pH and electrolyte concentration, determine how the resin complexes. After exchanging with appropriately changed ions in the digestive system, unbound drug molecules may diffuse away from the resin, releasing any attached drug molecules. Most cationic medications, including those with an amine activity, are exchanged for sulfuric acid groups, which may be found in most ion-exchange resins now employed in sustained release pharmaceuticals.

Examples:

• Amphetamine
• phenyl-butylamine (phentermine)
• phenyltoloxamine
  5. Dyslipidaemia

The major cause of mortality and disability worldwide is cardiovascular disease (CVD). They are also the main murderers. Significant factors include ischemic stroke and other (MI) and coronary heart disease (CHD). The combined effects of all these illnesses are catastrophic for society, healthcare, and personal health. Dyslipidaemia is a significant independent risk factor for cardiovascular diseases since it has been connected to the pathogenesis of coronary disease. Dyslipidaemia is increasing globally, not only in wealthy nations, as a consequence of poor nutrition and other lifestyle changes. ¹² In addition to high levels of LDL cholesterol and low levels of HDL cholesterol, dyslipidaemia is often characterized by excessive triglyceride levels (World Health Organization, 2003). Any one of these dyslipidaemias has the potential to be deadly. The presence of fatty deposits in the arterial walls is the most obvious indicator of lipid issues. When cholesterol crystallizes, it causes a chain of events that includes cell division and the growth of fibrous tissue, which leads to atheroma. Low-density lipoprotein (LDL) and intermediate-density lipoprotein (IDL) are lipoproteins that contribute to atherosclerosis. Plaques that constrict the arteries may lead to atherosclerosis. Cardiovascular issues including heart attacks, blocked arteries, peripheral artery disease, and stroke are most often caused by atherosclerosis. It could also be a factor in certain health issues. Heart disease risk is decreased when plasma low-density lipoprotein cholesterol is lower. Heart issues might result from excessively high blood cholesterol levels. Two other factors include hypertension and smoking.

1. 6. Polymers used in Matrix Tablet

Hydrogels: In the category known as polyhydroxyl ethyle methyl acrylate (PHEMA), some examples include cross-linked poly vinyl alcohol (PVA), cross-linked poly vinyl pyrrolidone (PVP), cross-linked polyethylene-oxide (PEO), and cross-linked poly-acrylamide (PA).

Soluble polymers: Poly-ethylene glycol (PEG), poly-vinyl alcohol (PVA), Poly-vinyl pyrrolidone PVP), Hydroxy propyl methyl cellulose (HPMC).

Biodegradable polymers: Polylacticacid (PLA), Polyglycolicacid (PGA), Polycaprolactone (PCL), Polyanhydrides, Polyorthoesters

Non-biodegradable polymers: Poly ethylene vinyl acetate (PVA), Poly dimethyl siloxane (PDS), Poly etherurethane (PEU), Poly vinylchloride (PVC), Cellulose acetate (CA), Ethyl cellulose (EC).

1.7 Mechanisms of Sustained Drug Release

SDR systems operate through various mechanisms to control the release rate of the drug:

• Diffusion-Controlled Systems: In these systems, the drug is dispersed within a polymer matrix.
• Dissolution-Controlled Systems: These systems rely on the dissolution of the drug or its carrier in the gastrointestinal tract. The release rate is controlled by the dissolution rate of the drug or the rate at which the carrier material dissolves.
• Osmotic-Controlled Systems: These systems utilize osmotic pressure to drive the release of the drug. Water enters the system through a semipermeable membrane, dissolving the drug and causing it to be expelled through an orifice at a controlled rate.

1.7.1 Erosion-Controlled Systems: In these systems, the drug is embedded in a biodegradable polymer matrix. The release rate is controlled by the erosion of the polymer, which gradually releases the drug over time.

MATERIAL AND METHOD

Materials from several sources were used in this investigation. Merril life science, Roorkee, provided a complimentary sample of rosuvastatin. Lactose, SCMC, and HPMCK4M were purchased from psychotropoc in Haridwar. Sun Pharma company in Paonta shaib was the source of additional excipients, including magnesium stearate.

1. 1. Determination of melting point

Assessing the melting point A fused tube of capillary with one end should contain the medicine verapamil hydrochloride, which should be put inside a digital melting point device (Perfit India, Model No. REC2802582). A medication's melting point is the temperature at which it starts to melt.

2.2 Standard Curve for Rosuvastatin Calcium

To prepare the first stock solution, 100 milligrams of calcium rosuvastatin were precisely measured out, and then the resulting concentration was adjusted by adding 100 milliliters of methanol ( CH3OH). The stock solution for component II (100 mL) was made by first removing 10 mL from the solution described above and then diluting it with 0.1 mL of hydrochloric acid. By adding 0.1M HCl to aliquots of stock solution II, we were able to produce final solution concentrations of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg. These values were achieved. Following that, an ultraviolet spectrophotometer with a wavelength of 245 nm was used to compare the absorbance to a blank of 0.1M HClas. In the following graph, concentration was shown as a function of absorbance.

2.3 Compatibility study using FT-IR

The formulation of a stable and effective solid dosage form is strongly dependent on the excipients that are used. These excipients should aid with the controlled distribution of the drug, increase its bioavailability, and protect it from degradation while doing so. Using IR-spectral analysis and keeping a watchful look out for variations in drug peak intensities in the spectra of physical drug combinations, it is possible to find evidence of drug-excipient interactions. In order to accomplish this goal, the peak concentrations of the medication throughout time were tracked and monitored.

2.3.1 Procedure

One milligram of the drug was mixed with three hundred milligrams of potassium bromide that had been dried at a temperature ranging from 120 to 130 degrees Celsius. The drying temperature was kept constant throughout the process. The temperature throughout the drying process ranged from 120 to 130 degrees Celsius. After the various components had been brought together, a transparent pellet was manufactured by subjecting them to 10 tons of pressure in a hydraulic press. This stage came after the previous one, in which the component pieces were assembled. A scan of the particle was performed using an infraredspectrophotometer at various wavelengths. The procedure stays the same no matter which of the required excipients are actually used in the process.

1. 4. Evaluation of Pre-formulation Parameters

2.4.2 Determination of angle of repose

Analyzing the angle of repose allows for the calculation of the frictional forces that are produced between the granule particles. The following illustration shows the maximum angle of deviation that may exist between the surface of the granule pile and the horizontal plane.

                   θ = tan-1 h/r

2.4.3 Determination of Bulk Density and Tapped Density

We calculated the starting volume by placing 25 grams of the combined substance (W1) into a measuring cylinder with a capacity of 100 milliliters. The cylinder was used to measure the volume. When it was finally given the get-ahead to enter the cylinder, the tap density equipment was already set up and ready to go. After the first 500 taps had been finished, the tapping process was continued for a further 750 taps after no further change in volume.

Bulk Density =   weight of powder

Bulk Volume

Tapped Density = weight of powder

Tapped Volume

2.4.4 Carr’s compressibility Index (CI) When calculating the compressibility index, measures, one may make use of either the bulk density or the tapped density. Generally speaking, the flowability of a material will improve as its compressibility becomes worse. Substances with levels in this characteristic that are lower than 20% may be expected to flow well.

2.4.5 Hausner’ s Ratio

It is a measurement that contrasts the bulk density of the granules with the density of the

granules after they have been tapped.

H= Tapped Density

Bulk Density

2.5 Post-Compression Evaluation Parameters

Evaluation of Rosuvastatin Calcium sustain release matrix tablets. The homogeneity of the drug content, the fluctuation in weight, the hardness, the friability, the thickness, and the in-vitro drug release utilizing various tablet surfaces were the evaluation criteria for tablets.

2.5.1Weight variation

During the manufacturing process, it is common practice to do a calculation to determine the tablet's weight. This is done with the goal of ensuring that each tablet contains the correct quantity of medication. The procedure begins with determining the average weight of 20 pills using their individual weights, followed by weighing 20 more pills individually and comparing their total weights to the average. This is what the USP test for weight fluctuation looks like. The tablets met the conditions set out by the USP, which say that no tablet may deviate by more than twice the permissible % and that no tablet may deviate by more than twice the permitted percentage. The tablets did comply with these requirements. Table 5.7 of the United States Pharmacopeia contains information on the official restrictions placed on percentage variation for tablets.

2.5.2 Tablet Hardnes

The tablet's ability to withstand the circumstances of shipping, storage, transit, and handling up to the point when it is eaten is directly proportionate to the tablet's level of hardness. A selection of tablets was chosen at random with the purpose of determining how delicate each one was. We are going to provide the average level of difficulty across all five criteria.

2.5.3 Friability

Friability refers to the phenomena in which the weight of the tablets while they are still contained in their containers decreases. Tablets are fragile because the many components of the tablet do not cling to one another in an adequate manner. After determining the starting weight of 20 tablets, the tablets are placed in a Roche friabilator and rotated 100 times at a speed of 25 revolutions per minute. The final weight of the tablets is then determined. The tablets were brushed to get rid of any leftover powder friabilator, then they were reweighed, and the results were recorded. For the purpose of calculating the friability %, the following formula was utilized:

Tablet Thickness

A uniform tablet size may be achieved by consistently maintaining the tablet's thickness. Vernier Callipers were used so that thickness could be gauged.

2.5.5 Drug Content Uniformity

Ten pills from each batch were weighed, and the average of the ten weights was used to calculate the weight of each batch. After being reduced to a powder, each tablet was then dissolved in phosphate buffer 6.8 in order to extract 40 mg of the active ingredient. Phosphate buffer with a pH of 6.8 was added so that the total amount could be increased to 100 ml. The stock solution (1 mL) was diluted with a pH 0.1M HCl buffer, and the resulting solution was used to fill a 10-mL volumetric flask with the remaining 9 mL. The absorbance at 245 nm was measured spectrophotometrically using a pH 0.1M HCl buffer as a blank after the solution was filtered. It was determined how much of the treatment was included in each individual pill.

2.5.6 In-vitro dissolution studies

The in-vitro dissolution test for rosuvastatin sustained-release tablets was performed in a USP type-II dissolution test equipment (Paddle type) with 900 ml of 0.1 N HCl as the dissolving medium for the first two hours, then phosphate buffer pH 7.4 at 50 rpm and temperature. Tested at a steady temperature. 37 ± 0.5°C. Throughout the experiment, a pre-filtered syringe extracted 5 cc of each sample. To replace the samples, an equal quantity of fresh dissolving medium was added at each interval. This ensured correct findings. The samples were examined after dilutions to check whether the medication was released. A UV-visible spectrophotometer recorded 245 nm absorption, completing this job. Three computations (n=3) were done to ensure accuracy.

2.6 Determination of λ max of Rosuvastatin Calcium

A UV spectrophotometer with 0.1 N HCl as the blank and 245 nm as the wavelength evaluated rosuvastatin calcium absorption. Absorbance was recorded and plotted versus concentration in a table The Rosuvastatin calibration curve graphic was created using water as the solvent. After dissolving 100 milligrams of the medication in a small amount of water, this quantity was added to 100 milliliters of water (1000 ppm) in a volumetric flask .Here, we'll take 1 milliliter of the solution and dilute it to a concentration of 100 parts per million by adding water. Take one milliliter of the above solution and dilute it with water to create ten milliliters (10 ppm). The stop solution was used to dilute the sample to concentrations of 0, 5, 10, 15, 20, 25, and 30 micrograms per milliliter. The absorbance was determined using the photometric technique at a wavelength of 245 nanometers. The regression coefficient, slope, and y axis intercept were determined after creating a calibration curve (standard plot) from the data.

1. 7. Compatibility studies using FT-IR

Using infrared spectroscopy with KBr disks, drug, polymer, and a mixture of the two spectrums were all generated. The samples were manufactured in KBr disks for 5 minutes at 5 tons of hydrostatic pressure, and the resultant spectra are shown in figures 6.2 through 6.10, respectively. It may be assumed that the drug and polymer combination is chemically compatible since all of the rosuvastatin calcium's distinctive peaks were seen in their spectra. The experiment's findings showed that the two chemicals were chemically stable when combined. The spectrum revealed no appreciable change in the medication's chemical composition.

2.2 Compatibility studies using FT-IR

2.8 Precompression study

2.8.1 Bulk density

The taped density was found to vary between 0.412±0.0046 to 0.472±0.0034

2.8.2 taped density

The taped density was found to vary between 0.506±0.0058 to 0.528±0.0052.

2.8.3 Angle of repose

The Angle of repose was found to vary between 27.42±0.024 to 32.22±0.026.

2.8.4 Compressibility index

The Compressibility index was found to vary between 10.43±1.29 to 14.62±2.56

2.8.5 Hausner ratio

The Hausner ratio was found to vary between 1.122 to 1.148.

2.9 Postcompression Study

2.9.1 Hardness

Before a tablet may be administered, its hardness must be evaluated to see how well it can hold up to typical storage, transit, and handling circumstances without capping, abrasion, or breaking. details the findings of testing the brittleness of all rosuvastatin calcium- controlled release matrix tablet formulations using the approach outlined in the methodology. We employed the Monsanto hardness tester to determine the degree of the material's fragility. The average hardness of all formulations is between 3.49 and 4.04 kg/cm2, depending on the kind. This guarantees that all batches of the mixture have safe handling characteristics.

Friability

To determine how well the tablets will withstand handling and shipping, their friability is evaluated. The tablets were put to the test using the Roche friabilator to determine how quickly they would shatter. The degree of friability of each formulation of controlled release matrix tablets was examined, Table 6.6 shows the results. The average friability of all formulations was 0.25–0.47%, much below the pharmacopoeial limit of 1%.

2.9.3 Weight variation test:

Homogeneous die fill was able to be used successfully for the manufacturing of tablets with consistent weights since the powder material was free-flowing. In accordance with the conditions of the IP, the weight fluctuation was permitted. The range of the weight variance across all formulations was determined to be between 199.31 and 202.01 mg, and the findings were compiled and shown in table no. 2.2 Because the percentage weight fluctuation was within the pharmacopoeial restrictions (5%), all of the tablets that were created were able to pass the test for weight variation

2.9.4 Drug content:

It was found that the drug concentration in formulations F1 through F9 ranged from 98.49%w/w to 99.64%w/w. It follows all of the rules and regulations. All results were summarized in Table 2.3

2.3 table post compression study

2.9.5 In-Vitro Drug Release Study

Our polymers were carbopol, HPMC-K4M, and sodium starch glycolate. This was done to test progressive medicine delivery. the in-vitro release data for rosuvastatin calcium sustain-release matrix tablets made from croscarmellose-HPMC-K4M and sodium starch glycolate-carbopol. The dissolving medium, croscarmellose concentration, sodium starch glycolate concentration, and polymer concentration most affected rosuvastatin calcium release in vitro from matrix tablet formulations. In-vitro rosuvastatin calcium release from matrix tablets decreases when tablets expand. The initial in vitro release study lasted two hours in 0.1 N hydrochloric acid. The experiment proceeded for 24 hours in a 6.8-pH phosphate buffer. The in-vitro release of rosuvastatin calcium peaked in the first and second six to seven hours for all formulations. After an hour, croscarmellose-HPMC-K4M tablets absorb 17.92% to 16.34% of Rosuvastatin Calcium, sodium alginate-carbapol tablets absorb 15.21% to 21.91%, and release retardant polymer tablets absorb 26.14%. Drug release decreased after six to seven hours. Due to Formulation F1's absence of a crosslinking agent, most medicines were released within 12 hours. Formulas F2, F3, F5, and F9 delivered medications in 16 hours, 20 hours, 16 hours, and 18 hours. These compositions decreased sodium starch glycolate and PVPK30. Since the full dosage was given before 24 hours, these formulations were not exceptional. Crosslinking agents and negatively charged polymers interacted less at pH 6.8. Thus, a porous, loose network accommodates a lot of dissolvable material. Formulations F4 and F7, which include the largest quantities of carbopol gum, sodium sodium glycolate, and HPMC-K4M, enhance the half-life of rosuvastatin calcium to 24 hours